Rebecca is a drug regulatory and patent litigation lawyer in Toronto who applies both her legal and scientific expertise to strategically advise and support clients.
Rebecca received her JD from the University of Toronto in 2005 and was called to the bar in 2006. Rebecca also obtained a Ph.D. in microbiology from the University of Guelph. Rebecca’s Ph.D. dissertation focused on the purification and characterization of osmoregulatory proteins of Escherichia coli. She has significant research experience in biochemistry, molecular biology, and microbiology. Prior to joining Markwell LLP, Rebecca practised at several international law firms.
Rebecca’s legal and scientific background allows her to uniquely understand clients’ technology, business objectives, and product portfolios in support of their patent litigation and regulatory matters.
Rebecca frequently represents life sciences and pharmaceutical industry clients in patent litigation matters and strategic product regulatory advice, including on matters related to Canada’s Patented Medicines Prices Review Board (PMPRB).
Since 2021, Rebecca has been selected as one of Canada’s top patent professionals in the IAM Patent 1000 rankings. She has co-authored a number of scientific and legal publications, including in the AUTM Journal, Biochemistry, Journal of Bacteriology and the Food and Drug Law Institute Update.
Rebecca is a member of the Toronto Intellectual Property Group (TIPG), the Intellectual Property Institute of Canada (IPIC), the Law Society of Ontario (LSO), the Ontario Bar Association (OBA) and the Canadian Bar Association (CBA).
